Mirum Pharmaceuticals, Inc.
DE ˙ DB ˙ US6047491013
77,12 € ↑0,96 (1,26%)
2026-06-05
DEL PRIS
SecurityDE:08D / Mirum Pharmaceuticals, Inc.
InstitutionEventide Asset Management, Llc
Latest Disclosed Ownership2,093,582 shares
Ownership 4.10%
Eventide Asset Management, Llc ownership in 08D / Mirum Pharmaceuticals, Inc.

2026-02-13 - Eventide Asset Management, Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,093,582 shares of Mirum Pharmaceuticals, Inc. (DE:08D). This represents 4.1 percent ownership of the company. In their previous filing dated 2025-02-14 , Eventide Asset Management, Llc had reported owning 2,606,938 shares, indicating a decrease of -19.69 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-02-13 2026-02-13 13G/A 2,606,938 2,093,582 -19.69 4.10 -24.49
2025-02-14 2025-02-14 13G/A 3,445,363 2,606,938 -24.33 5.43 -24.79
2024-11-14 2024-11-14 13G/A 2,693,581 3,445,363 27.91 7.22 24.91
2024-02-14 2024-02-14 13G/A 2,057,000 2,693,581 30.95 5.78 3.21
2023-02-14 2023-02-14 13G 2,057,000 5.60

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 1,408,871 -684,711 -32.71 130,113 -21.32 2.1518
2026-02-13 2025-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 2,093,582 -428,981 -17.01 165,370 -10.57 2.5832
2025-11-14 2025-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 2,522,563 -114,922 -4.36 184,923 37.77 3.0404
2025-08-14 2025-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 2,637,485 110,485 4.37 134,224 17.89 2.3517
2025-05-15 2025-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 2,527,000 -79,938 -3.07 113,851 5.62 2.2680
2025-02-14 2024-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 2,606,938 -838,425 -24.33 107,795 -19.78 1.9629
2024-11-14 2024-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 3,445,363 -169,457 -4.69 134,369 8.72 2.3160
2024-08-13 2024-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 3,614,820 314,420 9.53 123,591 49.07 2.1156
2024-05-15 2024-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 3,300,400 636,751 23.91 82,906 5.44 1.3001
2024-02-20 2023-12-31 13F/A-1 MIRUM PHARMACEUTICALS COM 604749101 2,663,649 -1,294,930 -32.71 78,631 -37.14 1.2835
2024-02-14 2023-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 3,613,649 -344,930 79,790 1.3021
2023-11-14 2023-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 3,958,579 499,378 14.44 125,091 39.78 2.2483
2023-08-15 2023-06-30 13F MIRUM PHARMACEUTICALS COM 604749101 3,459,201 1,400,000 67.99 89,490 80.92 1.5124
2023-05-15 2023-03-31 13F MIRUM PHARMACEUTICALS COM 604749101 2,059,201 2,201 0.11 49,462 23.31 0.9075
2023-02-13 2022-12-31 13F MIRUM PHARMACEUTICALS COM 604749101 2,057,000 782,000 61.33 40,112 49.73 0.7910
2022-11-14 2022-09-30 13F MIRUM PHARMACEUTICALS COM 604749101 1,275,000 1,275,000 26,788 0.5270
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.